Sublingual immunotherapy (SLIT) in a standard American allergy practice
The Internet Journal of Asthma, Allergy and Immunology · 2008
DOI: 10.5580/18d2 ↗At a glance
Journal article in The Internet Journal of Asthma, Allergy and Immunology, 2008.
Abstract (original language)
Subcutaneous Immunotherapy (SCIT) has been used in the United States with little modification for almost 100 years. It has been proven effective in the treatment of allergic disease not responsive to pharmacotherapy and appears to prevent the emergence of asthma in the pediatric population affected with allergic rhinitis. It is also effective in the treatment of Hymenoptera venom allergy, and drug allergy. The standard protocol for the treatment of all allergic disease requires injections twice a week for up to 6 months with maintenance biweekly or monthly shots lasting 3 to 5 years. Rush schedules are also possible though they appear to carry higher risks to patients.
Cite
APA
(2008). Sublingual immunotherapy (SLIT) in a standard American allergy practice. The Internet Journal of Asthma, Allergy and Immunology. https://doi.org/10.5580/18d2
Vancouver
Sublingual immunotherapy (SLIT) in a standard American allergy practice. The Internet Journal of Asthma, Allergy and Immunology. 2008. doi:10.5580/18d2
BibTeX
@article{euvimed2008,
title = {Sublingual immunotherapy (SLIT) in a standard American allergy practice},
journal = {The Internet Journal of Asthma, Allergy and Immunology},
year = {2008},
doi = {10.5580/18d2}
}
EUVIMED